TGTX
TG Therapeutics Inc
NASDAQ: TGTX · HEALTHCARE · BIOTECHNOLOGY
$42.86
-0.38% today
Updated 2026-05-08
Market cap
$6.59B
P/E ratio
15.04
P/S ratio
9.40x
EPS (TTM)
$2.86
Dividend yield
—
52W range
$25 – $44
Volume
2.2M
WallStSmart proprietary scores
68
out of 100
Grade: B
Buy
Investment rating
8.3
Growth
A5.8
Quality
C+9.0
Profitability
A+4.7
Valuation
C4/9
Piotroski F-Score
Moderate
-0.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$48.14
+12.32%
12-Month target
$30.20
-29.54%
Intrinsic (DCF)
$19.63
Margin of safety
-46.82%
1 Strong Buy6 Buy1 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 65.90% — above average
+ ROE 112.60% — strong efficiency
+ Revenue growth 69.60% QoQ
Risks
- Altman Z -0.51 — distress zone
- Negative free cash flow $-17.95M
- 46.82% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.79M | $233.66M | $329.00M | $616.29M | $700.35M |
| Net income | $-223.81M | $12.67M | $23.38M | $447.18M | $19.78M |
| EPS | — | — | — | — | $2.86 |
| Free cash flow | $-176.18M | $-31.41M | $-40.56M | $-24.99M | $-17.95M |
| Profit margin | -8,036.34% | 5.42% | 7.11% | 72.56% | 65.90% |
Peer comparison
Smart narrative
TG Therapeutics Inc trades at $42.86. representing a P/E of 15.04x trailing earnings. Our Smart Value Score of 68/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -0.51, it sits in the distress. TTM revenue stands at $700.35M. with profit margins at 65.90%. Our DCF model estimates intrinsic value at $19.63.
Frequently asked questions
What is TG Therapeutics Inc's stock price?
TG Therapeutics Inc (TGTX) trades at $42.86.
Is TG Therapeutics Inc overvalued?
Smart Value Score 68/100 (Grade B, Buy). DCF value $19.63.
What is the price target of TG Therapeutics Inc (TGTX)?
The analyst target price is $48.14, representing +12.3% upside from the current price of $42.86.
What is the intrinsic value of TG Therapeutics Inc (TGTX)?
Based on our DCF model, intrinsic value is $19.63, a -46.8% margin of safety versus $42.86.
What is TG Therapeutics Inc's revenue?
TTM revenue is $700.35M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-0.51 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.40x
ROE112.60%
Beta1.68
50D MA$32.85
200D MA$31.89
Shares out0.15B
Float0.14B
Short ratio—
Avg volume2.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—